• Ligand Pharmaceuticals director Jason Aryeh sold 2,161 common shares, according to a Form 4 filed Nov. 3, 2026.
• Sales on Oct. 30 totaled 1,461 shares at prices ranging from $317.74 to $320.49.
• A further 700 shares were sold Nov. 2 at $320.4261 per share.
• Following the transactions, Aryeh held 108,758 shares directly and 8,000 shares indirectly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ligand Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001376960-26-000005), on November 03, 2026, and is solely responsible for the information contained therein.